Novo Nordisk disclosed top-line results showing oral semaglutide failed to slow clinical progression in two large phase III Alzheimer’s trials. The studies enrolled more than 3,800 patients with early symptomatic disease and confirmed amyloid pathology and tested Rybelsus (oral semaglutide) versus placebo on standard-of-care backgrounds. Novo said the trials did not meet their primary cognitive and functional endpoints and that detailed data will be released to the scientific community. The negative readouts undercut hopes that GLP‑1 receptor agonists could be repurposed as disease‑modifying therapies for Alzheimer’s, a high-profile hypothesis pursued across industry and academia. Shares and sentiment in incretin-weight-loss and neurodegeneration pipelines may shift as investors and drug developers reassess Alzheimer’s strategies tied to metabolic mechanisms.